1093397-20-6

Basic information

• Product Name: lithium 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate
• Synonyms: lithium 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate
• CAS NO: 1093397-20-6
• Molecular Weight: 284.2
• Mol File: 1093397-20-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: lithium 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: lithium 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate(1093397-20-6)
• EPA Substance Registry System: lithium 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate(1093397-20-6)

Safety Data

• Hazardous Substances Data: 1093397-20-6(Hazardous Substances Data)

Upstream product

• 7377-26-6 4-Methoxycarbonylbenzoyl chloride 
• 1093397-18-2 methyl 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate 
• 942215-54-5 3-amino-4-hydroxy-5-methylbenzonitrile 
• 1689-89-0 nitroxynil 
• 849353-44-2 4-hydroxy-3-methyl-5-nitro-benzonitrile 

Downstream Products

• 1093397-19-3 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)-N-({1-[4-(trifluoromethyl)phenyl]piperidin-4-yl}methyl)benzamide 

Relevant articles and documents

CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems ofthe industrialized world In formula I, A-B is an arylamide moiety